Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months

Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.

Drug Resistant Epilepsy

Cholecalciferol

Placebo Oral

Vitamine D in Drug Resistant Epilepsy

Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy

Total score at baseline and after Vitamin D treatment (range 0-200; higher values=worse outcome)

Total score at baseline and after Vitamin D treatment (range 0-42; higher values=worse outcome)

Global score at baseline and after Vitamin D treatment (the higher score, the better outcome)

Vitamin D levels and percentage reduction in the seizure frequency compared to the reference period

Vitamin D level and type of AED (enzyme inducer versus non enzyme inducer drugs)

Vitamin D level and dose of AED (low dose versus high dose of enzyme inducer drugs)

Responder rate after Vitamin D treatment. Percentage of patients having a reduction of at least 50% of the seizure frequency

Percentage of patients without any seizure (seizure freedom)

Responder rate in focal and generalized epilepsy

Percentage of reduction of secondary generalized seizures and epileptic falls in respect to the reference period

Centre Hospitalier St Anne

APHP

FFRE

LFCE

Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate

Hyperparathyroidism, Primary

Osteoporosis

During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).

cinacalcet

During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).

hypercalciuria/гадене

Vitamine D in Drug Resistant Epilepsy

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

Най-пълната база данни за лечебни билки, подкрепена от науката